RxDoctor Payments Data

William Fukuda, MD

Internal Medicine · Newport Beach, CANPI 1396701850

Payments from drug & device makers

$720in general payments, 2019–2025

Across 39 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$160
  • AstraZeneca$160
  • AbbVie$67
  • Johnson & Johnson$44
  • GSK$43
  • Esperion Therapeutics, Inc.$36
  • plus $210 from 10 others

What the payments were for

  • Food & beverage$720100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$720 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$359,255
Medicare patients
543
Services billed
16,007

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban68$74,139
EliquisApixaban73$64,110
OzempicSemaglutide51$63,283
JardianceEmpagliflozin30$37,137
TrulicityDulaglutide28$28,251
MounjaroTirzepatide14$14,565
FarxigaDapagliflozin Propanediol11$14,141
NexletolBempedoic Acid16$9,185
SynthroidLevothyroxine Sodium67$7,304
Losartan Potassium622$6,485
Breo ElliptaFluticasone/Vilanterol17$6,050
GemtesaVibegron12$6,048
QuviviqDaridorexant Hcl11$5,456
Rosuvastatin Calcium275$5,381
Atorvastatin Calcium562$4,959

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$44$74,13968 claims
PfizerEliquis, Paxlovid$36$68,39894 claims
Novo NordiskOzempic$22$63,28351 claims
AstraZenecaFarxiga$160$14,14111 claims
Esperion Therapeutics, Inc.Nexletol$36$9,18516 claims
AbbVieSynthroid$67$7,30467 claims
GSKBreo Ellipta$43$6,05017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →